Vabysmo now covered across all three approved indications in the province, providing patients with a single, comprehensively funded solution MISSISSAUGA, ON- Hoffmann-La Roche Limited (Roche Canada) is pleased to announce… Read More
Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the potential for… Read More
At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GI All Cohorts followed to 9 months have maintained… Read More
Health Canada has approved ELAHERE® , the first novel therapy to demonstrate statistically significant and clinically meaningful improvements in overall survival (OS) compared to chemotherapy alone for patients with platinum-resistant… Read More
Allschwil, CH– Idorsia Ltd. continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sleep 2025, a global scientific congress… Read More
